Anthony Higham, SERB CEO

Ex­clu­sive: Af­ter win­ning le­gal bat­tle, for­mer Phase­Bio in­vestor finds US buy­er for its PhI­II drug to re­verse Bril­in­ta

Hav­ing wran­gled con­trol of a blood thin­ner re­ver­sal agent, SFJ Phar­ma has found a buy­er for the drug.

SERB Phar­ma­ceu­ti­cals, a spe­cial­ty phar­ma that vast­ly ex­pand­ed its port­fo­lio through sev­er­al merg­ers in re­cent years, is pick­ing up US rights to ben­tracimab, which is de­signed to re­verse the an­ti-co­ag­u­lat­ing ef­fects of As­traZeneca’s Bril­in­ta (tica­grelor). Phase­Bio orig­i­nal­ly li­censed the drug from As­traZeneca’s for­mer bi­o­log­ics arm Med­Im­mune, and SFJ hopped aboard mid­way with de­vel­op­ment fund­ing. But when Phase­Bio sound­ed an alarm bell re­gard­ing the com­pa­ny’s fi­nances, SFJ de­mand­ed rights to the drug — and won the le­gal bat­tle ear­li­er this year. In the process, Phase­Bio al­so filed for Chap­ter 11 bank­rupt­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.